Ustekinumab

Drug Profile

Ustekinumab

Alternative Names: Anti-interleukin-12 p40 monoclonal antibody; CNTO-1275; STELARA; Stelara; Stellara; Sterrara; Suterara

Latest Information Update: 17 Jul 2017

Price : $50

At a glance

  • Originator Centocor; Medarex
  • Developer Centocor; Janssen Biotech; Janssen Pharmaceutical KK; Janssen Research & Development; Janssen-Cilag
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Interleukin 12 subunit p40 inhibitors; Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Crohn's disease; Plaque psoriasis; Psoriatic arthritis
  • Phase III Spondylarthritis; Ulcerative colitis
  • Phase II Atopic dermatitis; Systemic lupus erythematosus
  • Phase I Inflammation
  • Discontinued Multiple sclerosis; Palmoplantar pustulosis; Primary biliary cirrhosis; Rheumatoid arthritis; Sarcoidosis

Most Recent Events

  • 14 Jul 2017 The UK's NICE recommends ustekinumab for Plaque psoriasis (In adolescents)
  • 24 May 2017 Launched for Crohn's disease in Japan (IV)
  • 19 Apr 2017 Janssen initiates enrolment in a phase III trial for Crohn's disease in United Kingdom and Belgium (NCT03107793)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top